Dravet Syndrome Breakthrough: New Drug Shows 91% Seizure Reduction

Top Summary

• What happened: A clinical trial showed a 91% seizure reduction in children with Dravet syndrome using the investigational drug zorevunersen.
• Why it matters: Dravet syndrome is a rare, drug-resistant form of epilepsy, and this breakthrough offers a potential new treatment option.
• What changes for people: Families may have access to a more effective treatment, improving the quality of life for children with Dravet syndrome.
• Who is affected: Children with Dravet syndrome, their families, and healthcare providers in India and globally.

Understanding Dravet Syndrome in India

Epilepsy affects 1 to 1.5 million children in India. It’s a neurological condition marked by unusual electrical activity in the brain. Symptoms include staring spells, confusion, shaking, and loss of consciousness.

Dravet Syndrome is a rare, genetic form of epilepsy beginning in infancy. It’s characterized by frequent, drug-resistant seizures and developmental delays.

The Indian Council of Medical Research (ICMR) estimates that 6 to 8 children per 1,000 have pediatric epilepsy. Dravet syndrome accounts for a critical segment of these cases.

The Zorevunersen Breakthrough

A new clinical trial published in The New England Journal of Medicine found that the drug zorevunersen led to a 91% reduction in seizures in children with Dravet syndrome. The trial was conducted by University College London and Great Ormond Street Hospital.

The drug boosts protein production from the healthy SCN1A gene copy. Dravet Syndrome is often caused by a mutation in the SCN1A gene.

The trial involved 81 children and showed improved cognition and behavior markers, along with a high seizure reduction rate. Mild side effects were recorded.

Limited Treatment Options in India

Currently, treatment options for Dravet Syndrome in India are limited. Many children still experience uncontrolled seizures despite available therapies.

Access to new therapies and genetic testing is restricted to specialty hospitals. The ICMR reports gaps in access to effective treatment in rural and remote areas.

 

“90% of patients continue to suffer from inadequate seizure control despite using therapies.” - Epilepsy and Behaviour Journal

 

What This Means for India

This breakthrough highlights the need for international policy to dispense rare disease treatments. Clinical trials for rare diseases need to be expanded in India.

The ICMR and the Indian Epilepsy Society play vital roles in bridging research and patient care. This is especially important in areas with limited access.

India needs to participate in global epilepsy research to ensure access to new therapies.

Addressing the Challenges

Key hindrances to establishing specialized care include:

• Awareness of the number of affected children
• Funding for research
• Accessibility to tested therapies

Expanding awareness, increasing funding, and improving access are crucial steps.

What to Watch Next

The research is moving to phase 3, and further trials are needed to confirm the long-term effectiveness and safety of zorevunersen. India should consider participating in these trials and adapting new therapies to ensure children receive effective treatment options.